logo
Klarna Secures New License from UK's Financial Conduct Authority

Klarna Secures New License from UK's Financial Conduct Authority

Bloomberg3 days ago
Klarna Group Plc said it has received an electronic money institution license for its UK division, which could lay the ground work for the Swedish fintech to more directly compete against the likes of Revolut Ltd. and Monzo Bank Ltd. for retail bank customers.
The approval means Klarna — which is best known for its buy now, pay later services — will be able to offer its 11 million UK customers accounts where they can save funds, according to a statement. It will also allow Klarna to launch a debit card in the UK.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

DSV AS (DSDVF) Q2 2025 Earnings Call Highlights: Navigating Market Challenges with Strategic ...
DSV AS (DSDVF) Q2 2025 Earnings Call Highlights: Navigating Market Challenges with Strategic ...

Yahoo

time30 minutes ago

  • Yahoo

DSV AS (DSDVF) Q2 2025 Earnings Call Highlights: Navigating Market Challenges with Strategic ...

Gross Profit (GP): Increased despite market challenges; Schenko contributed 925 million for two months. Synergies: Expected to deliver 500 million this year from Schenko integration. Transaction Costs: Estimated at 2 to 2.5 billion for the year. Net Interest Cost: Increased due to Schenko acquisition. Cash Flow: Nearly 4 billion in the quarter; 76 billion paid for Schenko business. Net Working Capital: Reduced to 2.4% of revenue. Debt Ratio: Gear ratio around 3, ahead of expectations. EBIT Guidance: Reiterated full-year guidance between 9.5 and 21.5 billion. Warning! GuruFocus has detected 11 Warning Signs with FRA:E0E. Release Date: July 31, 2025 For the complete transcript of the earnings call, please refer to the full earnings call transcript. Positive Points DSV AS (DSDVF) reported solid financial performance despite challenging market conditions, with growth in gross profit (GP) driven by the integration of Schenker. The company maintained its full-year outlook, indicating confidence in its strategic direction and operational resilience. DSV AS (DSDVF) successfully negotiated a constructive agreement with the German Works Council, paving the way for smoother integration of Schenker employees. The integration of Schenker is on track, with expected synergies of 500 million this year, contributing to long-term growth. DSV AS (DSDVF) has a strong cash flow position, with nearly 4 billion generated in the quarter, supporting its financial stability and strategic initiatives. Negative Points DSV AS (DSDVF) missed its guidance slightly due to foreign exchange fluctuations, impacting financial results. The road and contract logistics segments underperformed, with significant losses in Schenker's US operations and challenges in the German, UK, and Norwegian markets. The company faces higher transaction and integration costs, with expectations to spend over 2 billion this year. There is uncertainty regarding the full realization of synergies, with only 75% expected by the end of 2027, indicating potential delays. DSV AS (DSDVF) anticipates a higher tax rate during the integration period, affecting net earnings. Q & A Highlights Q: Can you provide an update on customer attrition and the impact of FX on your financials? A: Michael Ebbe, CFO: We have a hedging policy in place for up to 6 months, which helps mitigate FX impacts. We don't foresee an acceleration in FX losses. Jens Lund, CEO: We've intensified our dialogue with customers, which has been positively received. We are focused on maintaining GP rather than just volume, and we are confident in achieving a solid outcome. Q: Could you share details on the agreement with the German Works Council and why synergies are expected to take until 2027? A: Jens Lund, CEO: The agreement involves compensation factors for employees, and we are currently working on optimizing operations in Germany. The timeline for synergies is due to the complexity of infrastructure consolidation, but we are working to accelerate this process. Q: What scenarios could lead to a year-over-year decline in EBIT in the second half? A: Jens Lund, CEO: The guidance reflects current uncertainties, including geopolitical factors and integration challenges. While volumes have shown some improvement, the European economy remains a concern. We will reassess the guidance in the next quarter. Q: Can you explain the differences in yield between Schenker and legacy DSV, and the impact of US contract logistics headwinds? A: Jens Lund, CEO: Schenker's yields are lower due to different operational focuses, such as less emphasis on own box volumes. We are aligning operations to improve yields. In the US, a significant site loss has been addressed, reducing deficits from $8 million to $1-2 million for the rest of the year. Q: What are your plans for IT systems post-acquisition, and could share buybacks occur earlier than expected? A: Michael Ebbe, CFO: We are on track with synergies and hope to accelerate share buybacks. Jens Lund, CEO: For IT, we are evaluating Schenker's platform, which is more modern and cost-effective. We aim to integrate systems efficiently to control costs and improve operations. For the complete transcript of the earnings call, please refer to the full earnings call transcript. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Newcastle Reject Liverpool's £120m Bid for Alexander Isak
Newcastle Reject Liverpool's £120m Bid for Alexander Isak

Yahoo

time30 minutes ago

  • Yahoo

Newcastle Reject Liverpool's £120m Bid for Alexander Isak

Record breaking move blocked as Magpies demand £150m for Swedish star Newcastle Reject Liverpool's £120m Bid for Alexander Isak Newcastle United've reportedly rejected huge £120 million bid from Liverpool for striker Alexander Isak, in what could have become the most expensive transfer in British football history. Liverpool's Offer Falls Short According to the Daily Star, the Reds submitted official offer worth 120 million sterling poud but Newcastle immediately turned it down insisting that the Sweden international's valued at £150 million and isn't for sale this summer. Isak's Stunning Rise Signed in summer 2022 from Real Sociedad for £63 million , Isak's rapidly become one of the Premier League's top forwards. Last season he made 42 appearances, scoring 27 goal & providing 6 assists cementing his place as a key figure in Eddie Howe's squad. No Deal for Now Despite Liverpool's interest, Newcastle are holding firm with no plans to part ways with the 24 year old unless their massive valuation is met. With the transfer window heating up, Isak's future remains one of the biggest stories to watch.

Higher Tariffs on Swiss Imports May Lead to Pricier Nespresso Products and Watches
Higher Tariffs on Swiss Imports May Lead to Pricier Nespresso Products and Watches

Yahoo

time44 minutes ago

  • Yahoo

Higher Tariffs on Swiss Imports May Lead to Pricier Nespresso Products and Watches

Key Takeaways President Donald Trump unveiled plans to impose a 39% tariff on Swiss imports—the fourth highest import tax in his most-recent list of "reciprocal" tariffs. The import tax could lead to higher prices on Nespresso products and watches, executives said. Some $18.9 billion in pharmaceutical products were imported from Switzerland last year, and could also be subject to a sector-specific goods may soon be subject to steep tariffs that could drive up the price for Nespresso products, pharmaceuticals and watches in the U.S. President Donald Trump announced plans to impose a 39% tariff on goods from Switzerland beginning August 7th. That's the fourth-highest rate unveiled by the White House in its latest list of "reciprocal" tariffs, which are an attempt to rebalance trade with nations that buy less than they sell to the U.S. Switzerland's General Counsel in a series of messages on the social network X said the tariffs come "despite the progress made in bilateral talks and Switzerland's very constructive stance from the outset" and that it "continues to seek a negotiated solution" with the U.S. Switzerland had a $38.5 billion trade deficit with the U.S. in 2024, according to the Office of the U.S. Trade Representative. The U.S. imported $63.4 billion worth of goods from Switzerland last year, including $18.9 billion in pharmaceutical products, nearly $15 billion in precious metals, pearls and stones, $6.4 billion in clocks and watches, and $4.6 billion in organic chemicals, according to data downloaded from the U.S. Department of Commerce. Companies paying import taxes may price the expense into their U.S. rates. One retailer, the U.K.-based Watches of Switzerland Group PLC, has already seen its U.S. partners raise prices by a mid-single digit percent, CFO Anders Romberg said on a quarterly earnings call in July. At that point, the tariff rate was 10%. 'Our view is that some brands are looking to share the tariff pain with retailers rather than passing the full cost on to the consumers,' Romberg said, according to a transcript made available by AlphaSense. Nespresso machines and coffee are among the few products the Swiss-based Nestlé imports into the U.S., company leaders said on a conference call in April. Price increases were among the 'mitigating actions' under consideration, CFO Anna Manz said, according to a transcript. But Nestlé cited rising commodity prices when talking about its coffee-price increases on a conference call in July. The outlook for pharmaceuticals is harder to gauge, with Trump floating a 200% tariff on the sector. Some products that are critical for U.S. national security may get exemptions, said Thomas Schinecker, CEO of Switzerland-based Roche Holdings. The company was moving inventory into the U.S. and ramping up production of medicines made here, Schinecker told investors in July. 'We've had a number of discussions with the U.S. government, and there is clearly this idea that was mentioned before that there is a transition time for pharma companies,' Schinecker said, according to a transcript. Read the original article on Investopedia Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store